AR and prostate carcinoma: Hormone therapies like androgen receptor antagonists (e.g., enzalutamide) and androgen synthesis inhibitors (e.g., abiraterone) are increasing the occurrence of a subtype of prostate cancer that is negative for the androgen receptor and can progress via AI oncogenic signaling cascades [12–14].